Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00489112
Other study ID # 0044-07-EMC
Secondary ID
Status Recruiting
Phase Phase 4
First received June 19, 2007
Last updated June 25, 2007

Study information

Verified date June 2007
Source HaEmek Medical Center, Israel
Contact DORON PEREZ, M.D.
Phone +972-4-6495115
Email perez_do@clalit.org.il
Is FDA regulated No
Health authority Israel: Ministry of Health
Study type Interventional

Clinical Trial Summary

We will performe a prospective randomized study to evaluate the effects of the addition of alfuzocine xl 10 mg once a day for the conservative treatment of selected ureteral stones. A total of 60 patients with distal ureteral calculi will randomly divide into two treatment groups: group A (n=30) who will receive only analgetic therapy(Dipyrone)and diclofenac i.m. 75mg and group B (n=30) who will receive the same therapy plus alfuzocin xl (10 mg/daily) for a maximum of 2 weeks.No significant differences will be between the groups for age, gender distribution and mean stone size measured in the single largest dimension at presentation.Randomization will be done only with the patients permission after they had read a summary describing the goals of conservative management and a description of the drugs they would be taking. Potential side effects and complications of the drugs were discussed. The expulsion rate will the primary end-point of this study.


Recruitment information / eligibility

Status Recruiting
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Stone in the distal ureter until 1 cm of diameter

Exclusion Criteria:

- Evidence of urinary tract infection or sepsis

- Moderate or severe hydronephrosis

- Acute renal failure

- Ureteral stricture

- Stone with >1cm of diameter

- Previuos use of alpha blocker

- Pregnancy

- Previuos ureteral endoscopic or open surgery

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label


Intervention

Drug:
Alfuzocine XL 10 mg once a day


Locations

Country Name City State
Israel Haemek Medical Center Afula
Israel Haemek medical center,urology department Afula

Sponsors (1)

Lead Sponsor Collaborator
HaEmek Medical Center, Israel

Country where clinical trial is conducted

Israel,